BioScience Health Innovations annual operating cash flow
2020
2021
2022
2022
2023
2024
2025
BioScience Health Innovations Operating Cash Flow Growth & History (BHIC)
BioScience Health Innovations's operating cash flow was $172,178 for fiscal 2025.
View full BioScience Health Innovations company overviewBioScience Health Innovations annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $172,178 | $148,990 | +642.53% |
| 2024 | 2024-12-31 | $23,188 | $331,030 | — |
| 2023 | 2023-12-31 | −$307,842 | −$125,063 | — |
| 2022 · Dec 31 | 2022-12-31 | −$182,779 | — | — |
| 2022 · Aug 31 | 2022-08-31 | −$85,782 | −$56,343 | — |
| 2021 | 2021-08-31 | −$29,439 | −$21,757 | — |
| 2020 | 2020-08-31 | −$7,682 | — | — |
BioScience Health Innovations quarterly operating cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q2.22
Q3.22
Q3.22
Q3.22
Q1.23
Q1.23
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$541,874 | −$826,884 | — |
| Q1 2026 | 2026-03-31 | −$552,107 | −$880,416 | — |
| Q4 2025 | 2025-12-31 | −$100,696 | −$50,391 | — |
| Q3 2025 | 2025-09-30 | −$340,445 | −$392,678 | — |
| Q2 2025 | 2025-06-30 | $285,010 | $215,710 | +311.27% |
| Q1 2025 | 2025-03-31 | $328,309 | $376,349 | — |
| Q4 2024 | 2024-12-31 | −$50,305 | $6,152 | — |
| Q3 2024 | 2024-09-30 | $52,233 | $122,611 | — |
| Q2 2024 | 2024-06-30 | $69,300 | $183,634 | — |
| Q1 2024 | 2024-03-31 | −$48,040 | $18,633 | — |
| Q4 2023 | 2023-12-31 | −$56,457 | — | — |
| Q3 2023 | 2023-09-30 | −$70,378 | $19,519 | — |
| Q2 2023 | 2023-06-30 | −$114,334 | −$104,121 | — |
| Q1 2023 · Mar 31 | 2023-03-31 | −$66,673 | −$65,724 | — |
| Q1 2023 · Feb 28 | 2023-02-28 | −$19,550 | $5,477 | — |
| Q1 2023 · Nov 30 | 2022-11-30 | −$27,910 | −$22,009 | — |
| Q3 2022 · Sep 30 | 2022-09-30 | −$89,897 | — | — |
| Q3 2022 · Jun 30 | 2022-06-30 | −$10,213 | — | — |
| Q3 2022 · May 31 | 2022-05-31 | −$46,651 | −$43,442 | — |
| Q2 2022 · Mar 31 | 2022-03-31 | −$949 | — | — |
| Q2 2022 · Feb 28 | 2022-02-28 | −$25,027 | −$7,359 | — |
| Q1 2022 | 2021-11-30 | −$5,901 | −$5,323 | — |
| Q4 2021 | 2021-08-31 | −$7,984 | −$5,089 | — |
| Q3 2021 | 2021-05-31 | −$3,209 | $1,402 | — |
| Q2 2021 | 2021-02-28 | −$17,668 | −$23,607 | — |
| Q1 2021 | 2020-11-30 | −$578 | $5,537 | — |
| Q4 2020 | 2020-08-31 | −$2,895 | — | — |
| Q3 2020 | 2020-05-31 | −$4,611 | — | — |
| Q2 2020 | 2020-02-29 | $5,939 | — | — |
| Q1 2020 | 2019-11-30 | −$6,115 | — | — |
BioScience Health Innovations operating cash flow trends
Between the periods ended 2020-08-31 and 2025-12-31, BioScience Health Innovations's operating cash flow increased from −$7,682 to $172,178, a change of $179,860. The latest reported quarter, Q2 2026, shows −$541,874.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioScience Health Innovations source filings ↗